Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 05 October, 2024
Author: Getaka|Social: Getaka Financial Services X (Earlier Twitter) Profile Getaka Financial Services LinkedIn Logo

Ind-Swift Laboratories Ltd: Intrinsic Value and Fundamental Analysis

Share Price and Basic Stock Data

Last Updated: October 5, 2024, 12:33 am

Market Cap 750 Cr.
Current Price 127
High / Low186/81.8
Stock P/E5.63
Book Value 158
Dividend Yield0.00 %
ROCE19.6 %
ROE17.4 %
Face Value 10.0
PEG Ratio0.98

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Ind-Swift Laboratories Ltd

Competitors of Ind-Swift Laboratories Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Industry Average0 Cr0000%0.59%0.49%0

All Competitor Stocks of Ind-Swift Laboratories Ltd

Quarterly Result

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Sales226227250236247307280310313304310290288
Expenses178185199180194270227251259241250224236
Operating Profit48425156523753595464606652
OPM %21%18%21%24%21%12%19%19%17%21%19%23%18%
Other Income9367821788-16677
Interest26242424242324242222202121
Depreciation2028141421821616159141314
Profit before tax12-8192516-4720262416323924
Tax %0%-264%1%3%-1%-30%1%2%-13%255%45%18%19%
Net Profit12-29192416-61202528-25173219
EPS in Rs1.95-4.943.184.142.71-10.403.364.294.65-4.252.925.363.29

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Sales1,4091,1349656606537167657577808911,0391,207
Expenses1,2311,063906571546610631630635709837978
Operating Profit178725989107106134126144183202229
OPM %13%6%6%13%16%15%18%17%19%21%19%19%
Other Income334-19-31115161203323377
Interest851401171171068828921071009692
Depreciation40546684858887104908713157
Profit before tax87-119-142-143-83-553650-20181387
Tax %-3%1%14%17%29%29%39%42%-7%117%117%45%
Net Profit89-118-122-119-59-392229-21-3-248
EPS in Rs23.50-30.02-29.79-29.14-14.33-8.754.856.09-3.59-0.53-0.368.06
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2012-20132013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-2023
YoY Net Profit Growth (%)-232.58%-3.39%2.46%50.42%33.90%156.41%31.82%-172.41%85.71%33.33%2500.00%
Change in YoY Net Profit Growth (%)0.00%229.19%5.85%47.96%-16.52%122.51%-124.59%-204.23%258.13%-52.38%2466.67%

Ind-Swift Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2012-2013 to 2022-2023.

Growth

Compounded Sales Growth
10 Years:3%
5 Years:11%
3 Years:13%
TTM:-19%
Compounded Profit Growth
10 Years:14%
5 Years:42%
3 Years:260%
TTM:338%
Stock Price CAGR
10 Years:14%
5 Years:25%
3 Years:24%
1 Year:35%
Return on Equity
10 Years:0%
5 Years:5%
3 Years:10%
Last Year:17%

Last Updated: Unknown

Balance Sheet

Last Updated: Unknown

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Equity Capital394142424546486060606059
Reserves814684553476486507540581544541622872
Borrowings1,2401,3551,4131,4571,2421,0831,1481,0311,00595386217
Other Liabilities280258236240364387188198210247280217
Total Liabilities2,3742,3392,2442,2152,1382,0231,9241,8701,8181,8011,8241,165
Fixed Assets1,1711,1741,1171,0991,0429349148437536305878
CWIP161781137870692011191080
Investments1717181818181917362930111
Other Assets1,0251,0709971,0201,0071,0029729981,0111,1311,1991,047
Total Assets2,3742,3392,2442,2152,1382,0231,9241,8701,8181,8011,8241,165

Reserves and Borrowings Chart

Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity -47098799673-64125135150195-163
Cash from Investing Activity -480-35-29-31-17-12-9-105-13-104
Cash from Financing Activity 660-64-48-69-62100-133-124-141-186699
Net Cash Flow-290-13-4-623-17114-4431

Free Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Free Cash Flow178.0071.0058.0088.00106.00105.00133.00125.00143.00182.00-751.00-633.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days13316821520818219416918617716015348
Inventory Days1801823123683052912843153012882426
Days Payable811031201379111811412411111811352
Cash Conversion Cycle2322474074393963673393773673302822
Working Capital Days246277379255110993053133032902674
ROCE %2%0%1%2%2%4%4%5%7%7%13%20%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Aug 2024
Promoters42.00%42.00%42.00%42.01%42.01%42.01%42.01%42.01%42.01%42.01%42.01%42.01%
FIIs0.22%0.06%0.00%0.00%0.04%0.00%0.08%0.17%0.31%0.26%1.27%0.84%
DIIs19.50%19.49%19.49%19.49%19.49%19.49%19.49%19.49%18.73%8.03%0.94%0.94%
Public38.29%38.44%38.50%38.51%38.48%38.52%38.44%38.34%38.96%49.72%55.81%56.22%
No. of Shareholders24,52825,34224,91024,22624,45623,39722,96225,40524,63322,43925,46129,536

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue10.0010.0010.0010.0010.00
Basic EPS (Rs.)71.248.10-0.36-0.53-4.28
Diluted EPS (Rs.)71.248.10-0.36-0.53-4.28
Cash EPS (Rs.)80.3517.5921.5514.0711.52
Book Value[Excl.RevalReserv]/Share (Rs.)157.6483.3667.6165.6669.48
Book Value[Incl.RevalReserv]/Share (Rs.)157.64114.02100.47100.90107.12
Revenue From Operations / Share (Rs.)216.78201.87173.68149.04130.36
PBDIT / Share (Rs.)50.7043.9239.9834.3629.73
PBIT / Share (Rs.)41.6834.3318.0719.7714.67
PBT / Share (Rs.)98.4614.472.103.01-3.31
Net Profit / Share (Rs.)71.338.00-0.35-0.52-3.54
NP After MI And SOA / Share (Rs.)71.247.96-0.35-0.52-3.54
PBDIT Margin (%)23.3821.7523.0123.0522.80
PBIT Margin (%)19.2217.0010.4013.2611.25
PBT Margin (%)45.417.161.202.02-2.53
Net Profit Margin (%)32.903.96-0.20-0.35-2.71
NP After MI And SOA Margin (%)32.863.94-0.20-0.35-2.71
Return on Networth / Equity (%)45.199.54-0.53-0.80-5.09
Return on Capital Employeed (%)26.0914.137.367.865.67
Return On Assets (%)36.132.60-0.11-0.17-1.13
Long Term Debt / Equity (X)0.011.512.102.252.14
Total Debt / Equity (X)0.011.732.352.562.48
Asset Turnover Ratio (%)0.850.660.540.460.39
Current Ratio (X)2.993.143.223.002.67
Quick Ratio (X)2.941.961.941.811.61
Inventory Turnover Ratio (X)2.671.521.331.231.19
Interest Coverage Ratio (X)5.862.852.502.051.65
Interest Coverage Ratio (Post Tax) (X)1.681.810.970.960.80
Enterprise Value (Cr.)165.501173.711328.011424.061150.03
EV / Net Operating Revenue (X)0.120.971.281.601.48
EV / EBITDA (X)0.554.475.556.936.47
MarketCap / Net Operating Revenue (X)0.450.270.380.480.16
Price / BV (X)0.620.660.981.100.31
Price / Net Operating Revenue (X)0.450.270.380.480.16
EarningsYield0.720.14-0.01-0.01-0.16

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Ind-Swift Laboratories Ltd as of October 5, 2024 is: ₹157.88

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of October 5, 2024, Ind-Swift Laboratories Ltd is Undervalued by 24.31% compared to the current share price ₹127.00

Intrinsic Value of Ind-Swift Laboratories Ltd as of October 5, 2024 is: ₹166.98

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of October 5, 2024, Ind-Swift Laboratories Ltd is Undervalued by 31.48% compared to the current share price ₹127.00

Last 5 Year EPS CAGR: 5.77%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
    1. The stock has a low average ROCE of 5.58%, which may not be favorable.
    2. The stock has a high average Working Capital Days of 237.33, which may not be favorable.
    3. The stock has a high average Cash Conversion Cycle of 315.42, which may not be favorable.
    4. The company has higher borrowings (1,067.17) compared to reserves (601.67), which may suggest financial risk.
    5. The company has not shown consistent growth in sales (515.92) and profit (-22.58).

    Stock Analysis

    • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ind-Swift Laboratories Ltd:
      1. Net Profit Margin: 32.9%
        • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
      2. ROCE: 26.09% (Industry Average ROCE: 0.59%)
        • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
      3. ROE%: 45.19% (Industry Average ROE: 0.49%)
        • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
      4. Interest Coverage Ratio (Post Tax): 1.68
        • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
      5. Quick Ratio: 2.94
        • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
      6. Stock P/E: 5.63 (Industry average Stock P/E: 0)
        • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
      7. Total Debt / Equity: 0.01
        • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
      The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
      Stock Rating:

    About the Company - Qualitative Analysis

    Ind-Swift Laboratories Ltd. is a Public Limited Listed company incorporated on 04/01/1995 and has its registered office in the State of Chandigarh, India. Company’s Corporate Identification Number(CIN) is L24232CH1995PLC015553 and registration number is 015553. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 988.09 Cr. and Equity Capital is Rs. 59.81 Cr. for the Year ended 31/03/2022.
    INDUSTRYADDRESSCONTACT
    PharmaceuticalsSCO 850, Shivalik Enclave, NAC, Manimajra, Chandigarh Chandigarh 160101investor@indswiftlabs.com
    http://www.indswiftlabs.com
    Management
    NamePosition Held
    Mr. Navrattan MunjalChairman & Managing Director
    Mr. Himanshu JainJoint Managing Director
    Mr. Rishav MehtaExecutive Director
    Mr. Sahil MunjalExecutive Director
    Dr. Ashwani Kumar VigIndependent Director
    Mr. Rajinder Kumar GuptaIndependent Director
    Mr. S P SharmaIndependent Director
    Ms. Neerja ChathleyIndependent Woman Director

    FAQ

    What is the latest fair value of Ind-Swift Laboratories Ltd?

    The latest fair value of Ind-Swift Laboratories Ltd is ₹157.88.

    What is the Market Cap of Ind-Swift Laboratories Ltd?

    The Market Cap of Ind-Swift Laboratories Ltd is 750 Cr..

    What is the current Stock Price of Ind-Swift Laboratories Ltd as on 05 October 2024?

    The current stock price of Ind-Swift Laboratories Ltd as on 05 October 2024 is ₹127.

    What is the High / Low of Ind-Swift Laboratories Ltd stocks in FY 2024?

    In FY 2024, the High / Low of Ind-Swift Laboratories Ltd stocks is 186/81.8.

    What is the Stock P/E of Ind-Swift Laboratories Ltd?

    The Stock P/E of Ind-Swift Laboratories Ltd is 5.63.

    What is the Book Value of Ind-Swift Laboratories Ltd?

    The Book Value of Ind-Swift Laboratories Ltd is 158.

    What is the Dividend Yield of Ind-Swift Laboratories Ltd?

    The Dividend Yield of Ind-Swift Laboratories Ltd is 0.00 %.

    What is the ROCE of Ind-Swift Laboratories Ltd?

    The ROCE of Ind-Swift Laboratories Ltd is 19.6 %.

    What is the ROE of Ind-Swift Laboratories Ltd?

    The ROE of Ind-Swift Laboratories Ltd is 17.4 %.

    What is the Face Value of Ind-Swift Laboratories Ltd?

    The Face Value of Ind-Swift Laboratories Ltd is 10.0.

    About the Author

    Author Avatar
    Getaka

    Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

    Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Ind-Swift Laboratories Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE